20 Aug Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial
Posted at 09:40h
in Στεφ. Νόσος-Καρδιακή Ανεπάρκεια
ohn J.V. McMurray, MB, MD,a James B. Young, MD,b Mark E. Dunlap, MD,c Christopher B. Granger, MD,d James Hainer, MD,e Eric L. Michelson, MD,e Steven Earle, PhD,e Bertil Olofsson, PhD,f Jan O¨ stergren, MD,g Salim Yusuf, MD, DPhil,h Karl Swedberg, MD, PhD,i and Marc A....